HC Wainwright Issues Positive Forecast for Harrow (NASDAQ:HROW) Stock Price

Harrow (NASDAQ:HROW - Get Free Report) had its price objective raised by equities research analysts at HC Wainwright from $57.00 to $60.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 111.19% from the stock's current price. HC Wainwright also issued estimates for Harrow's Q2 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.10 EPS and FY2026 earnings at $0.40 EPS.

Separately, B. Riley cut their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Harrow Price Performance

Shares of Harrow stock traded up $2.79 during mid-day trading on Monday, reaching $28.41. 633,665 shares of the stock were exchanged, compared to its average volume of 498,289. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -30.22 and a beta of 0.41. Harrow has a fifty-two week low of $15.97 and a fifty-two week high of $59.23. The firm has a 50-day simple moving average of $25.02 and a 200 day simple moving average of $31.99.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. On average, sell-side analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Harrow by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock valued at $62,809,000 after buying an additional 5,225 shares during the period. Braidwell LP boosted its holdings in shares of Harrow by 5.5% during the 1st quarter. Braidwell LP now owns 956,839 shares of the company's stock worth $25,452,000 after buying an additional 49,800 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of Harrow by 6.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock worth $22,301,000 after purchasing an additional 41,896 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Harrow by 12.0% in the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company's stock worth $8,701,000 after purchasing an additional 35,006 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Harrow by 7.5% in the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after purchasing an additional 22,266 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.